On molecular level, we demonstrated that DPYSL5 expression is under AR regulation, and the NE phenotype is inducible with the clinically used second -generation AR inhibitor Enzalutamide (ENZ) in prostate cancer cells. The gene discussed is DPYSL5; the disease is prostate cancer.